阿西米尼联合伊马替尼、尼洛替尼或达沙替尼治疗慢性期或加速期慢性髓性白血病患者:1期研究最终结果
该1期剂量递增研究最终结果报告了阿西米尼联合伊马替尼、尼洛替尼或达沙替尼三组方案治疗既往接受过ATP竞争性TKI的慢性期或加速期CML患者的疗效与安全性。联合方案起效迅速但耐受性较阿西米尼单药下降,研究确定了各联合方案的扩展推荐剂量及最大耐受剂量。
要点
- 阿西米尼联合ATP竞争性TKI起效迅速,但耐受性较阿西米尼单药下降。
- 扩展推荐剂量:阿西米尼40 mg每日两次联合尼洛替尼300 mg每日两次。
- 扩展推荐剂量:阿西米尼40或60 mg每日一次联合伊马替尼400 mg每日一次;阿西米尼80 mg每日一次联合达沙替尼100 mg每日一次。
核心结论
- 阿西米尼联合ATP竞争性TKI在既往接受过ATP竞争性TKI治疗的慢性期或加速期CML患者中显示快速起效,但耐受性较阿西米尼单药下降。
研究设计与样本
- 1期剂量递增研究,最终结果来自阿西米尼联合尼洛替尼、伊马替尼或达沙替尼的3个联合治疗组。
主要发现
- 阿西米尼联合ATP竞争性TKI起效迅速,但耐受性较阿西米尼单药下降。
- 阿西米尼60 mg每日一次联合伊马替尼400 mg每日一次达到最大耐受剂量。
- 阿西米尼联合尼洛替尼或达沙替尼未达到最大耐受剂量。
关键数值与推荐
- 扩展推荐剂量为阿西米尼40 mg每日两次联合尼洛替尼300 mg每日两次。
- 扩展推荐剂量为阿西米尼40或60 mg每日一次联合伊马替尼400 mg每日一次。
- 扩展推荐剂量为阿西米尼80 mg每日一次联合达沙替尼100 mg每日一次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), synergizes with adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) to prevent emergence of and overcome resistance. Combination therapy may provide new treatment options for patients with chronic myeloid leukemia (CML) with suboptimal responses to ATP-competitive TKI monotherapy. Preliminary analysis of asciminib combined with nilotinib, imatinib, or dasatinib in a phase 1 dose-escalation study suggested promising efficacy and safety for patients with CML in chronic phase or accelerated phase treated with prior ATP-competitive TKIs; herein, we present final results from the 3 combination therapy arms. Asciminib, in combination with ATP-competitive TKIs, demonstrated rapid efficacy offset by a decreased tolerability compared with asciminib monotherapy. Based on these safety, tolerability, and preliminary efficacy results, asciminib 40 mg twice daily (BID) plus nilotinib 300 mg BID, asciminib 40 or 60 mg once daily (QD) plus imatinib 400 mg QD, and asciminib 80 mg QD plus dasatinib 100 mg QD were identified as recommended doses for expansion. The maximum tolerated dose was reached at asciminib 60 mg QD plus imatinib 400 mg QD and was not reached with asciminib plus nilotinib or dasatinib.
引用
- Cortes JE, Lang F, Rea D, et al. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 2025. PMID: 40204896. doi:10.1038/s41375-025-02592-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。